Management consideration in nonpulmonary visceral metastatic seminoma of testis.
10.3346/jkms.1999.14.4.431
- Author:
Dong Soo PARK
1
;
Debra M PROW
;
Robert J AMATO
;
Christopher J LOGOTHETIS
Author Information
1. Department of Urology, Pundang CHA Hospital, Pochon CHA University, Sungnam, Korea. dsparkmd@netsgo.com
- Publication Type:Original Article
- Keywords:
Seminoma;
Testis;
Neoplasm metastasis;
Therapeutics
- MeSH:
Adult;
Antineoplastic Agents, Combined/administration & dosage*;
Bone Neoplasms/secondary;
Bone Neoplasms/radiotherapy;
Bone Neoplasms/drug therapy;
Combined Modality Therapy;
Human;
Lung Neoplasms/secondary;
Lung Neoplasms/radiotherapy;
Lung Neoplasms/drug therapy;
Lymphatic Metastasis;
Male;
Middle Age;
Retroperitoneal Neoplasms/secondary*;
Retroperitoneal Neoplasms/radiotherapy;
Retroperitoneal Neoplasms/drug therapy*;
Retrospective Studies;
Seminoma/secondary*;
Seminoma/radiotherapy;
Seminoma/drug therapy*;
Testicular Neoplasms/pathology*
- From:Journal of Korean Medical Science
1999;14(4):431-437
- CountryRepublic of Korea
- Language:English
-
Abstract:
To develop a more appropriate therapeutic strategy for treatment of nonpulmonary visceral metastatic testicular seminoma based on the International Germ Cell Consensus Classification, we reviewed the medical records of patients with nonpulmonary visceral metastatic testicular seminoma who were treated over a 20-year period. Only 15 (2.2%) of the 686 cases of testicular seminoma were nonpulmonary visceral metastatic seminoma. The median age of patients was 38 years (range, 22-53 years). Ten (67%) of the patients had an initial diagnosis of supradiaphragmatic or visceral metastatic disease. In addition to nonpulmonary visceral metastasis, all patients had lymph node metastasis as well, the majority of which involved the retroperitoneal lymph nodes. The median and mean progression-free survival durations after chemotherapy for advanced disease were 19 months and 63.7 months, respectively. Six patients (40%) survived, five relapsed after radiation therapy and four died of chemorefractory disease not dependent on the specific regimen. Although the number of cases reviewed in this study was small, we conclude that the choice of chemotherapeutic regimen among the current treatments for nonpulmonary visceral metastatic seminoma of testis primary does not present a different outcome. Therefore, multimodality therapies using new strategies or new agents are well indicated.
